Tirzepatide vs. Semaglutide: New Research Reveals Surprising Metabolic Differences
May 23, 2025 / tirzepatide vs semaglutide metabolism / GLP-1 weight loss drugs / energy expenditure obesity treatment / fat oxidation in weight loss / tirzepatide metabolic effect
New research reveals tirzepatide temporarily boosts energy expenditure, while semaglutide initially reduces it during early treatment, despite both enhancing fat oxidation. These distinct metabolic effects may explain tirzepatide’s greater weight loss efficacy and inform future anti-obesity drug development.
Development of a silkworms-based evaluation system for the extracts and compounds for their obesity and lipid metabolism improving activity
May 23, 2025 / silkworm obesity model / SOLD lipid metabolism testing / non-mammalian drug screening / anti-obesity compound evaluation / epigallocatechin gallate effects
Researchers developed a silkworm-based model (SOLD) to evaluate anti-obesity and lipid metabolism-improving compounds, showing mammal-like responses to fenofibrate and epigallocatechin gallate, offering a non-mammalian alternative for screening therapies targeting obesity and related metabolic disorders.
Gut microbiota and weight management: What do we know and what should we do about it?
May 26, 2025 / gut microbiota and obesity / microbiome weight loss therapy / probiotics for fat reduction / gut-brain axis metabolism / dietary interventions microbiome
Emerging research links gut microbiota to energy metabolism, food preferences, and obesity risk. Targeting the gut with probiotics, prebiotics, and specific diets may enhance weight loss outcomes by modulating metabolic pathways and reducing inflammation, supporting microbiome-informed obesity interventions.
Phase 3 Clinical Study of Mazdutide in Chinese Adults with Overweight or Obesity (GLORY-1) Published in The New England Journal of Medicine (NEJM)
May 25, 2025 / Mazdutide obesity treatment / GLORY-1 clinical trial / dual GCG GLP-1 agonist / weight loss drug China / metabolic health NEJM study
Mazdutide, a dual GCG/GLP-1 receptor agonist, significantly reduced weight and improved metabolic parameters in Chinese adults with overweight or obesity in the Phase 3 GLORY-1 trial, supporting its clinical potential as a novel, effective obesity treatment.
Metabolic Dysfunction-Linked Steatotic Liver Disease Tied to Increased Preterm Birth Risk
May 23, 2024 / preclinical obesity cancer risk / excess adiposity cancer link / obesity classification framework / metabolic dysfunction and cancer / obesity-related cancer prevention
A Swedish nationwide study found that metabolic dysfunction-associated steatotic liver disease (MASLD) in pregnant women significantly increases the risk of preterm birth, highlighting MASLD as a high-risk obstetric condition requiring enhanced prenatal care and monitoring.
Cardiometabolic experts alarmed by young adult obesity, urge proactive measures
May 23, 2025 / young adult obesity / cardiometabolic syndrome / GLP-1 drug misuse / abdominal fat risk / cardiovascular prevention strategies
Rising abdominal obesity in young adults in Korea signals future cardiovascular risk, prompting experts to call for youth-focused prevention strategies and caution against cosmetic overuse of GLP-1 drugs like Wegovy and Mounjaro without medical necessity.
Identification of serum metabolic markers in non-obese hypertensive patients using non-targeted metabolomics
May 26, 2025 / non-obese hypertension / J-HTN biomarkers / serum metabolomics / LysoPC 22:6 / precision hypertension diagnosis
Researchers identified distinct serum metabolites, especially LysoPC(22:6/0:0), that differentiate non-obese hypertension (J-HTN) from other hypertensive types, offering potential for early detection and personalized treatment strategies through precision metabolomics.
BMI changes in adolescence mediate the effect of air pollution on metabolic health
May 20, 2025 / air pollution / adolescent BMI / insulin resistance / metabolic health / nitrogen oxides
Adolescent BMI growth mediates the link between childhood exposure to traffic-related air pollution and insulin resistance in young adulthood, highlighting a critical pathway contributing to metabolic dysfunction and the importance of early intervention in at-risk populations.
Landmark Study Shows Ozempic May Treat This Deadly Liver Disease
May 26, 2025 / semaglutide / MASH treatment / liver fibrosis / Ozempic study / metabolic liver disease
A Phase 3 trial shows semaglutide (Ozempic/Wegovy) significantly reduces liver inflammation and scarring in patients with MASH, potentially offering a dual benefit for liver and metabolic health. Results support its future role in treating this serious liver disease.
Association between insulin resistance indices and prevalence of knee osteoarthritis using the Korean National health and examination survey
May 25, 2024 / knee osteoarthritis / insulin resistance / TyG index / metabolic syndrome / Korean health survey
A Korean national survey found strong associations between insulin resistance indices—especially TyG-related metrics—and knee osteoarthritis, suggesting metabolic dysfunction may play a key role in OA development, even after adjusting for confounders like BMI and comorbid conditions.
Unilateral adrenalectomy for primary aldosteronism: New approach for bilateral adrenal disease
May 20, 2025 / primary aldosteronism / unilateral adrenalectomy / hypertension treatment / aldosterone excess / adrenal surgery
Mayo Clinic research shows that minimally invasive unilateral adrenalectomy can improve outcomes in patients with bilateral primary aldosteronism, reducing aldosterone levels, hypertension, and medication dependence—offering an alternative to lifelong pharmacologic management of this underdiagnosed hypertension-related endocrine disorder.
Study examines geographic ties between dementia and cardiometabolic disease in the US
May 24, 2025 / dementia prevention / cardiometabolic disease / Alzheimer’s risk factors / hypertension and dementia / geographic health disparities
A Barrow Neurological Institute study finds cardiometabolic diseases drive 37% of U.S. dementia cases, with the strongest link in Southern states. Reducing modifiable conditions like hypertension and diabetes could significantly lower dementia prevalence nationwide.
Differential benefits of 12-week morning vs. evening aerobic exercise on sleep and cardiometabolic health: a randomized controlled trial
May 26, 2025 / morning vs evening exercise / sleep and metabolism / aerobic exercise benefits / vascular health improvement / cholesterol reduction strategies
A 12-week aerobic exercise trial found morning workouts improved sleep timing, reduced cholesterol, and accelerated fat loss, while evening exercise yielded greater vascular benefits, including improved blood flow and lower systolic blood pressure, in sedentary adult males.
Meat-rich diets and a single gene variant may have contributed to the physiological evolution of modern humans
May 21, 2025 / ACSF3 gene variant / meat-rich diet evolution / human metabolic rate / height and genetics / metabolic disease genetics
A gene variant (rs34590044-A) increasing ACSF3 expression may have co-evolved with meat-rich diets in humans, promoting greater height and basal metabolic rate. These findings shed light on evolutionary adaptations and their link to modern metabolic disease risk.
Diabetes Drug Stops Prostate Cancer From Coming Back
May 22, 2025 / ‘pioglitazone prostate cancer / PPARγ and cancer / diabetes drug cancer prevention / prostate cancer relapse therapy / metabolic reprogramming in cancer
Pioglitazone, a PPARγ-activating diabetes drug, may prevent prostate cancer recurrence by altering cancer cell metabolism and inhibiting growth. Retrospective data show relapse-free outcomes in diabetic patients, supporting further clinical evaluation in broader prostate cancer populations.
Metabolic Risk and Self-Rated Health in Adults With T2DM
May 25, 2025 / self-rated health diabetes / metabolic syndrome T2DM / HbA1c and self-assessment / HDL-C in type 2 diabetes / diabetes primary care diagnostics
In adults with type 2 diabetes, poor self-rated health correlates with some metabolic abnormalities but offers limited diagnostic value beyond standard biomarkers like HDL-C and HbA1c. Clinical assessment remains essential for detecting metabolic dysfunction in primary care settings.
Multi-organ metabolome biological age implicates cardiometabolic conditions and mortality risk
May 26, 2025 / biological age metabolomics / cardiometabolic risk aging / MetBAG mortality prediction / metabolome aging clocks / UK Biobank plasma analysis>
Researchers developed plasma metabolome-based biological age gaps (MetBAGs) across five organ systems using UK Biobank data. These aging clocks predict cardiometabolic disease risk and mortality, offering insights into the genetic and metabolic underpinnings of human aging and health outcomes.
Patients with controlled psoriasis still face systemic inflammation, cardiometabolic risks
May 20, 2025 / psoriasis inflammation risk / residual inflammation cardiometabolic / biologics systemic inflammation / psoriasis CRP biomarkers / obesity psoriasis heart disease
Despite optimal skin control with biologics, over one-third of psoriasis patients experience persistent systemic inflammation, particularly those with higher BMI or female sex—highlighting ongoing cardiometabolic risk and the need for broader treatment strategies beyond skin symptom management.
Association between cardiometabolic index and abdominal aortic calcification in US adults from the NHANES
May 22, 2025 / cardiometabolic index AAC / visceral obesity aortic calcification / CMI cardiovascular risk / lipid metabolism AAC / NHANES CMI atherosclerosis
Higher cardiometabolic index (CMI), a marker of visceral obesity and lipid dysregulation, is significantly associated with increased abdominal aortic calcification and severe AAC risk, particularly in smokers, males, and individuals with prior cardiovascular events, highlighting its diagnostic utility.
Associations of common fats and oils with cardiometabolic health outcomes in the Framingham Offspring cohort
May 22, 2025 / butter type 2 diabetes / margarine cardiovascular risk / dietary fats metabolic health / non-hydrogenated oils LDL / Framingham fat intake study
In the Framingham Offspring cohort, moderate butter intake was linked to improved cardiometabolic markers and reduced type 2 diabetes risk, while higher margarine consumption increased risks for both diabetes and cardiovascular disease. Non-hydrogenated oils raised LDL-C and BMI.